GSK dismisses near-term split as new drugs offset falling Advair
London
GLAXOSMITHKLINE (GSK) said on Wednesday the chance of it spinning off or selling its consumer health business before 2018 was "extraordinarily low", arguing the group's strategy was delivering, helped by rising sales of new medicines.
Growing demand for recently launched HIV and respiratory drugs helped Britain's biggest drugmaker beat forecasts for fourth-quarter earnings by a small margin, lifting the shares in a sharply lower market.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Holiday Inn owner IHG’s Q1 revenue up 2.6%, leisure travel demand remains strong
WSJ moves Asia headquarters from Hong Kong to Singapore
South Korea to slap fines on food suppliers for ‘shrinkflation’
Olam outbids Dreyfus’ sweetened deal for Australia’s Namoi, raises offer to A$0.66 per share
Live Nation’s revenue beats estimates as boom in concerts drive ticket sales
Jim Beam owner bets on canned vodka cocktails to double revenue